Per the AP (via Erichson), markets are shrugging off the $134 million Nevada judgment (see Oct. 11) against the maker of the hormone-replacement drugs Prempro and Premarin. Earlier coverage of Wyeth victories is here, here and here. One stock analyst, citing expectations that the new award will be reduced or reversed, called it "more of a headline risk than a long-term financial risk".